Evotec expands open innovation push with Yale
The Pmlive website announced that Germany’s Evotec has entered into a strategic partnership with Yale University as it continues to adopt an open innovation approach to drug discovery. The latest agreement will see Evotec join forces with Yale on discovery science for a number of diseases with unmet medical need, including metabolic diseases, disorders of the central nervous system , immunological diseases and cancer. While the pharma industry has paid lip service to open innovation for years, it is only in recent times that momentum has started to build behind the concept, which hinges on integrating internal and external scientific expertise via the creation of networks of strategic R&D partners, both in academia and the private sector.
Click here to read the full article.